Teva has launched a fixed-dose combination inhaler for patients with asthma or COPD.
The DuoResp Spiromax inhaler, which launched last month, contains a combination of the corticosteroid budesonide and beta-2 agonist formoterol. The formulation also contains lactose particles, the taste of which reassures the patient that they have taken their dose, the manufacturer claims.
The breath-activated, dry-powder inhaler produces an even air pressure to blend the drug with the lactose particles and deliver a consistent dose even when not held vertically, Teva says.
DuoResp Spiromax can deliver medium strength doses of 160/4.5mcg (200/6mcg) or high strength doses of 320/9mcg (400/12mcg) and has an NHS list price of £29.97.
More information from Teva's medical information team on 0207 540 7117